An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers

An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers

We made an open label, multicenter, non-comparative study to assess the efficacy and safety of oral gatifloxacin, 400mg PO given once-daily during 7 to 14 days for the treatment of adult outpatients with community-acquired pneumonia at five Brazilian medical facilities. Among the 86 subjects availab...

Full description

Bibliographic Details
Main Author:	Antonio Carlos Nicodemo
Format:	Article
Language:	English
Published:	Elsevier
Series:	Brazilian Journal of Infectious Diseases
Subjects:	Gatifloxacin community-acquired pneumonia Brazil
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000100007&lng=en&tlng=en

Similar Items

An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers
by: Nicodemo Antonio Carlos
Published: (2003-01-01)

Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study
by: Franca Suelene Aires, et al.
Published: (2002-01-01)

Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study
by: Suelene Aires Franca, et al.

Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia
by: J.S. Mendonça, et al.

An open multicenter study of the use of gatifloxacin for the treatment of non-complicated acute bacterial rhinosinusitis in adults
by: L.L.M. Weckx, et al.

Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin
by: Eduardo Alexandrino Servolo Medeiros

Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin
by: Medeiros Eduardo Alexandrino Servolo
Published: (2002-01-01)

BROMATOMATRIC ASSAY OF GATIFLOXACIN IN PHARMACEUTICALS
by: KALSANG THARPA, et al.
Published: (2008-09-01)

Stability-indicating RP-HPLC method for simultaneous determination of gatifloxacin and flurbiprofen in binary combination
by: Islam Ullah Khan, et al.
Published: (2014-04-01)

Comparative Study of Ocular Pharmacokinetics of Topical 0.3% Gatifloxacin Eye Gel and Solution in Rabbits
by: Manli Liu, et al.
Published: (2022-04-01)

Performance characteristics of bioassay UV-spectrophotometry and high perfomance liquid chromatographic determination of gatifloxacin in tablets
by: Cristiani Capistrano Gonçalves de Oliveira Lopes, et al.
Published: (2008-01-01)

Efficacy and Safety of Prophylactic Intracameral Gatifloxacin Injection in Cataract Surgery: 1 Year Results
by: Ayşegül Penbe, et al.
Published: (2018-01-01)

Dissipation Dynamics of Doxycycline and Gatifloxacin and Accumulation of Heavy Metals during Broiler Manure Aerobic Composting
by: Lei Chu, et al.
Published: (2021-08-01)

Gatifloxacin Loaded Nano Lipid Carriers for the Management of Bacterial Conjunctivitis
by: Poorva H. Joshi, et al.
Published: (2023-08-01)

Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components
by: Patrícia Abreu Ferreira da Cunha, et al.
Published: (2013-06-01)

Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials
by: Qiaoling Ruan, et al.
Published: (2016-01-01)

Green method for quantification of gatifloxacin in eye drops using UV by eco-scale assessment
by: Max Well Silva Teixeira, et al.
Published: (2024-01-01)

Design of a Controlled-Release Delivery Composite of Antibacterial Agent Gatifloxacin by Spherical Silica Nanocarrier
by: Xueping Guo, et al.
Published: (2022-01-01)

A novel gatifloxacin-loaded intraocular lens for prophylaxis of postoperative endophthalmitis
by: Mengna Li, et al.
Published: (2023-02-01)

The use of complex formation manner for spectrophotometric analysis of gatifloxacin drug based on Co(II), Ni(II) and La(III) ions
by: Mona M. Mostafa, et al.
Published: (2021-01-01)

Stability indicating RP-HPLC method for simultaneous determination of gatifloxacin and dexamethasone in binary combination
by: Syed Naeem Razzaq, et al.
Published: (2017-04-01)

Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis
by: Marcianes P, et al.
Published: (2017-03-01)

Synthesis, structural, thermal, and morphological characterization of Ru(III) complex with gatifloxacin and its utility to obtain RuO2 nanostructures
by: Althubeiti Khaled
Published: (2024-03-01)

Gatifloxacin inducing apoptosis of stromal fibroblasts through cross-talk between caspase-dependent extrinsic and intrinsic pathways
by: Bin Xu, et al.
Published: (2019-10-01)

Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with community-acquired pneumonia: an open-label, non-comparative multicenter trial
by: Fernando G. Rubio, et al.

Community-acquired pneumonia /
by: Suttorp, N. (Norbert), 1953-, et al.
Published: (2007)

A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project
by: Merle Corinne SC, et al.
Published: (2012-05-01)

Hospital Acquired Pneumonia
by: Halis AKALIN, et al.
Published: (1999-12-01)

Dilemma of community-acquired pneumonia
by: Lamia H Shaaban
Published: (2019-01-01)

Etiology of severe community - acquired pneumonia in adults: results of the first Russian multicenter study
by: I A Zakharenkov, et al.
Published: (2020-01-01)

Features of laboratory indicators of severe community-acquired pneumonia
by: Pertzeva T.A., et al.
Published: (2017-06-01)

Antimicrobial therapy for community-acquired pneumonia in adults
by: Cunha Clovis Arns da, et al.
Published: (2002-01-01)

Antimicrobial therapy for community-acquired pneumonia in adults
by: Clovis Arns da Cunha, et al.

chlamydia pneumoniae unfection in - patients with community acquired pneumonia in Iraq
by: hayfaa D. Salman
Published: (2009-01-01)

Investigation of etiology of community-acquired pneumonia in hospitalized patients in a tertiary hospital of São Paulo City, Brazil
by: Daniel Joelsons, MD, PhD, et al.
Published: (2023-11-01)

Mycoplasma pneumonia and Chlamydia pneumonia infection in patients admitted to Beheshti Hospital in Kashan with community-acquired pneumonia
by: Mansoreh Momen Heravi, et al.
Published: (2023-12-01)

Тhe features of severe community acquired pneumonia
by: Avramenko I.V.
Published: (2015-06-01)

Nomogram for prediction of severe community-acquired pneumonia development in diabetic patients: a multicenter study
by: Ruoming Tan, et al.
Published: (2022-11-01)

Tigecycline and Community-Acquired Pneumonia
by: Sercan ULUSOY
Published: (2013-12-01)

PES Pathogens in Severe Community-Acquired Pneumonia
by: Catia Cillóniz, et al.
Published: (2019-02-01)